Old AUD Medications Remain Underused as GLP-1 Buzz Grows
Three FDA-approved meds (naltrexone, acamprosate, disulfiram) can treat alcohol use disorder but are widely underused due to stigma, limited clinician training, and marketing gaps, with only a fraction of diagnosed patients receiving them; meanwhile GLP-1 weight‑loss drugs (like Ozempic) are being studied for reducing drinking, but evidence is not yet conclusive, underscoring the need to treat alcohol use disorder like other chronic diseases by improving access and awareness.